venclyxto
abbvie ltd - venetoclax - leukemia, lymphocytic, chronic, b-cell - antineoplastic agents - venclyxto monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (cll) in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor.
venclexta tablet
abbvie corporation - venetoclax - tablet - 10mg - venetoclax 10mg - antineoplastic agents
venclexta tablet
abbvie corporation - venetoclax - tablet - 50mg - venetoclax 50mg - antineoplastic agents
venclexta tablet
abbvie corporation - venetoclax - tablet - 100mg - venetoclax 100mg - antineoplastic agents
venclexta kit
abbvie corporation - venetoclax; venetoclax; venetoclax - kit - 10mg; 50mg; 100mg - venetoclax 10mg; venetoclax 50mg; venetoclax 100mg - antineoplastic agents
venclyxto 100mg tablets
abbvie ltd - venetoclax - tablet - 100mg
venclyxto 50mg tablets
abbvie ltd - venetoclax - tablet - 50mg
venclyxto 10mg tablets
abbvie ltd - venetoclax - tablet - 10mg
ninlaro 3mg capsules
takeda uk ltd - ixazomib citrate - capsule - 3mg
ninlaro 2.3mg capsules
takeda uk ltd - ixazomib citrate - capsule - 2.3mg